Case study backs YolTech's AATD gene therapy
A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.
Newsletters and Deep Dive digital magazine
A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.
Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.
Fresenius is already a player in the biosimilars market, and has ramped up its position via a deal with WuXi Bio that spans up to 37 candidates.
Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.
Editor's Picks
Newsletters and Deep Dive
digital magazine